Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 91

  • 1 206 clinical trials
  • 460 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia80Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Plasma cell myeloma refractory42Follicular lymphoma41Mantle cell lymphoma33Myelofibrosis32B-cell small lymphocytic lymphoma29Chronic myeloid leukaemia29Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17Paroxysmal nocturnal haemoglobinuria17B-cell lymphoma refractory16B-cell type acute leukaemia16Anaemia14+340

Clinical trials in Blood and lymphatic system disorders

1 206 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 206 clinical trials

Mantle cell lymphoma refractory

Not recruiting

Study of Brexucabtagene Autoleucel in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Kite Pharma Inc.

Mantle cell lymphoma

Not recruiting

Study of Acalabrutinib, Venetoclax, and Rituximab for Patients with Newly Diagnosed Mantle Cell Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Acute myocardial infarction+5

Not recruiting

Study on the Effects of Zalunfiban for Patients with ST-Elevation Myocardial Infarction (Heart Attack)

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Zalunfiban
  • Sponsor:Celecor Therapeutics Inc.

Chronic myeloid leukaemia

Not recruiting

Study on Ponatinib for Patients with Chronic Myelogenous Leukemia in Molecular Response

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ponatinib
  • Sponsor:Fundacion Cris De Investigacion Para Vencer El Cancer

Thymoma+1

Not recruiting

Study on Pembrolizumab and Lenvatinib for Patients with Pre-Treated Thymic Carcinoma and B3-Thymoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Medica Scientia Innovation Research S.L.

Acute myeloid leukaemia

Not recruiting

Study of Venetoclax and Azacitidine for Patients with Acute Myeloid Leukemia After Stem Cell Transplant

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Diffuse large B-cell lymphoma

Not recruiting

Study on Lenalidomide, Tafasitamab, and Rituximab for Treating Diffuse Large B-Cell Lymphoma in Patients Aged 80 and Older

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Plasma cell myeloma

Not recruiting

Study Comparing Venetoclax and Dexamethasone with Pomalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pomalidomide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Follicular lymphoma+1

Not recruiting

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Study of Brentuximab Vedotin, Adriamycin, Vinblastine, and Dacarbazine for Children with Advanced Stage Hodgkin Lymphoma

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Brentuximab Vedotin
  • Sponsor:Takeda Development Center Americas Inc.

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Not recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Myelofibrosis

Not recruiting

Study of BMS-986158 Alone and with Ruxolitinib or Fedratinib for Patients with Intermediate or High Risk Myelofibrosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fedratinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab121 clinical trialsVenetoclax115 clinical trialsCyclophosphamide99 clinical trialsLenalidomide99 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.